Sansheng Pharmaceuticals Establish a private equity fund medical enterprise to contribute to the LP

"Daily Economic News" reporter was informed that recently, the China Securities Investment Fund Industry Association (hereinafter referred to as the China Foundation Association) announced the latest list of private equity fund managers who have successfully recorded the newly recorded private equity fund manager, including many highlights.

On August 5th, Liaoning Sansheng Private Equity Fund Management Co., Ltd. (hereinafter referred to as Liaoning Sansheng Private Equity) completed the record. It was established in January this year and has a registered capital of 5 million yuan. A market value of HK $ 12.926 billion) a subsidiary.

In addition, many well -known investors in the industry have "self -reliance" to participate in the initiative to set up a private equity institution. Among them, Shanghai Tianxing Private Equity Fund Management Co., Ltd. (hereinafter referred to as Tianxun Shi Private Equity), an executive partner of Panshi Capital and President Bai Ge, has recently completed the record. Another institution named Beijing Zhengxi Anhua Private Equity Fund Management Partnership (Limited Partnership) (hereinafter referred to as Zhengxi Anhua Private Equity), many executives behind them are invested from Hongyi, which has also attracted widespread attention from the industry.

Successfully filing to attract industry attention

On August 5th, the successful record of Liaoning Sanesheng Private Equity attracted the attention of the industry. This private equity fund manager was established in January this year, with a registered capital of 5 million yuan. The registered address and office address are in Shenyang City, Liaoning Province, with two full -time employees.

The reason why the industry is concerned is because Liaoning Sanesheng Private Equity is a private equity institution under the Sanxian Pharmaceutical of Biopharmaceuticals, which is set up by 100%of Liaoning Sansheng Pharmaceutical Co., Ltd., and the actual control of human 3SBIO Inc., that is, Sansheng Pharmaceutical. Public information shows that Sansheng Pharmaceutical is a company that is mainly engaged in development, production, marketing and sales of pharmaceutical products. The main products include reorganized human platelet generating vegetarian products, tumor necrosis factor α inhibitors, and reorganized people to promote redin.

"Daily Economic News" reporters learned through inquiry that Liaoning Sanesheng Private Equity is not the only private equity fund manager of San Life Pharmaceutical. In February 2017, the Liaoning Sansheng Biomedical Investment Fund Management Partnership (Limited Partnership) (hereinafter referred to as Liaoning Sansheng Biology) was established, and the record was completed in early 2019. This institution is set up by Shenyang Sansheng Pharmaceutical Co., Ltd. and Deguang (Tianjin) Investment Partnership (Limited Partnership) each subscribed for 50%of the establishment, managed a fund, that is, the Liaoning Sansheng medical industry established in 2017 Investment fund partnership (limited partnership). It is worth noting that the Liaoning Sansheng Bio has an institutional integrity information (information submitting abnormal) and institutional prompt information (the investor's targeted disclosure account opening rate is low).

In fact, in recent years, listed medical companies have become normal. According to the incomplete statistics of reporters, more than 20 listed pharmaceutical companies have issued an announcement for participating or initiating the establishment of an industrial investment fund since this year. The enthusiasm is evident. At the same time, these companies are no longer satisfied with only simple financial investors, and they have begun to set up their own private equity institutions, whether it was Guangzhou Guangyao Capital Private Fund, which was previously a subsidiary of Guangyao Group, or this time Liaoning San San San San San San San San San San Liaoning San San San San San San of Liaoning Shengfeng is a very typical representative.

Well -known investors have also participated in

Among these newly recorded private equity, there are several senior management teams behind them that have attracted the attention of reporters because they are all well -known investors in the industry before. For example, Tianxing Weishi Private Equity, which was established in November last year and recently completed, has a registered capital of 10 million yuan and 5 full -time employees. Its legal representative, general manager, and executive director Bai Ge is a well -known investor in the VC/PE industry.

According to public information, Bai Ge has more than ten years of experience in the strategic development, investment mergers and acquisitions, and corporate management experience of the Internet, mobile Internet and wireless communication companies. He has worked at Shanghai Bell Alcatel Co., Ltd. M & A and investment enterprise management. Since then, he has worked in touch technology and grand, and is responsible for the strategy, investment mergers and acquisitions, investment enterprises, listed and corporate financing. In November 2014, he joined Panshi Capital and served as the executive partner and CEO. The company he invested included Shanda Literature, Wanhe Tianyi, Himalayan, Baidu Takeaway, and Blue Whale Media.

The filing information also shows that the three investors of Tianxing Weishi Private Equity are Shanghai Feihuai Investment Co., Ltd. (37%of the subscription), Shanghai Zidanchen Enterprise Management Center (limited partnership) (33%of the subscription ratio) and Zhejiang Zhuji Huifeng Entrepreneurship Investment Co., Ltd. (30%), actively controlling people.

There are also a number of executives behind the new private equity from the old PE Hongyi investment, which is Zhengxi Anhua Private Equity. Zhengxi Anhua Private Equity was established in June this year, with a registered capital of 10 million yuan and 6 full -time employees. His executive partner (appointment representative) and actual controller Jiang Suwen are a very senior first -level market investor. In 2006, he served as an analyst at the China Construction Bank Investment Banking Department. In 2007, he entered the Meilin Real Estate Fund as an analyst ; In 2011, he joined Beijing Hongyi Far Investment Consultant Co., Ltd. as a senior investment manager in the PE Investment Department. Capital also served as the managing director until he participated in the establishment of Zhengxi Anhua Private Equity.

It is worth noting that another executive of the agency, Zhou Nanyang, the person in charge of compliance risk control, also came from Hongyi Investment.In 2016, he joined the Hongyi Investment Strategy Research and Business Development Department as an analyst. In 2019, he joined the investment manager of Hongyi Jinyong Asset Management (Shenzhen) Co., Ltd.Jin Yong Investment, a wholly -owned subsidiary of managed.According to public information, Jinyong Investment Headquarters is located in Hong Kong, China, and the investment business originated from the hedge fund department of Hongyi Investment.The licenses have office sites in Beijing, Shanghai, and Shenzhen.After Zhengxi Anhua's private equity was established, Zhou Nanyang joined and served as the person in charge of compliance control.Daily Economic News

- END -